抗肿瘤坏死因子α（anti-TNF）剂在治疗炎症性肠病的安全性和有效性方面的大多数研究都涉及少数黑人患者。我们的目标是评估黑人炎症性肠病患者治疗反应率与白人患者相比的情况。我们对接受抗TNF治疗的炎症性肠病患者进行了回顾性评估，并评估了那些治疗药物浓度的患者的临床、内窥镜和放射学反应。我们确定了符合纳入标准的118名患者。与白人患者相比，黑人炎症性肠病患者的内窥镜和放射学活动病变的患病率显著更高（分别为62%和34%，P = 0.023），尽管相似的比例达到治疗剂量（分别为67%和55%，P = 0.20）。此外，黑人患者在抗TNF剂治疗期间的炎症性肠病相关住院率显著高于白人患者（分别为30%和13%，P = 0.025）。黑人炎症性肠病患者在抗TNF剂治疗中活动病变的患病率更高，与白人患者相比有更多的炎症性肠病相关住院情况。 ©作者2023年。由牛津大学出版社代表Crohn’s & Colitis基金会出版。版权所有。有关使用权限，请发送电子邮件至：journals.permissions@oup.com。

Most studies on the safety and efficacy of antitumor necrosis factor alpha (anti-TNF) agents in the treatment of inflammatory bowel disease have included few Black patients.We aimed to evaluate the therapeutic response rate in Black IBD patients compared with White patients.We conducted a retrospective review of IBD patients who were treated with anti-TNF agents and assessed those with therapeutic drug levels for clinical, endoscopic, and radiologic response to anti-TNF treatment.We identified 118 patients who met the inclusion criteria. Black IBD patients had significantly higher prevalence of endoscopic and radiologic active disease compared with White patients (62% and 34%, respectively; P = .023), despite similar proportions reaching therapeutic titers (67% and 55%, respectively; P = .20). Moreover, Black patients had significantly higher rate of IBD-related hospitalizations than White patients (30% vs 13%, respectively; P = .025) while on anti-TNF agents.Black IBD patients on anti-TNF agents had a significantly higher prevalence of active disease and more IBD-related hospitalizations than White patients.© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.